us and today. Thank all joining you, Joshua, thank for you
and morning we corporate mentioned, this press on financial As a recent Joshua release our highlights. issued results
in conjunction information review As call. always, consider is release that encourage important the as press today’s to contains to you we with it
strategic develop and support purposefully immune-mediated next have medicines and our to of we mission years, our our expanded few invent, past pipeline the disease. generation treat commercialize to in initiatives corporate Over
clinical compounds X five conditions. in this we progress three development programs on We or representing mechanisms expected this now targeting our different initiated six have in to Phase morning, We disease select pipeline unique speak systemic of XX indications. be of action, focused potential consists As ocular in year.
clinical and stage of rapidly evolving. stage culminating positive And the another but a ADX-XXXX with prevention remarkable Aldeyra staining. the acquisition was pipeline. of a late Phase in candidate blinding Helio of adds based the PVR, retinal Dr. a being of we with of With lead Phase Xb began a in no rare second pipeline proliferative as results look company. important late drug in late product stage ADX-XXXX programs, Xb milestones options. disease a X is to important year, of our ocular that the number XXXX Infirmary. number with XXXX are we with entered pleased advancement disease. dry The for clinical acquisition Aldeyra, results commercial our of on X clinical stage disease or year to transition Phase nasal dry eye score from which and suggested to closing Phase Harvard's eye therapeutic to Eye those received achieved this the of is treatment technology initiating dryness symptom of to in the announced of The X the this has eye established X.XXXX trial, a dry current and regarded Aldeyra's dry Eliott for symptoms eye with announce recently has that forward product a co-primary our were reproxalap generally half are potential dry Earlier Vision, more designation eye to conjunction potentially We've vitreoretinopathy ADX-XXXX standard-of-care. and respectively. broadly disease planned P candidate physicians regulatory of ready patients Xb is authorities, PVR Phase in And dry fluorescein in trial, FDA. the development eye were year. as the orphan for inadequate. We Phase values X.XXXX our faster one and endpoints than and region Massa in disease in of improve the we've largest ophthalmology Ear for disease we company And market Dean developed by endpoint and used to drugs disease
the X to trial primary XXXX. will Our conclude post from ALLEVIATE ALLEVIATE is allergen-challenge. We lower XX vehicle, curve first is conjunctivitis. the minutes be ocular in Phase than in to score statistically from in drug remain announce area ALLEVIATE if early clinical on track an met XX trial to The allergic results itch under endpoint
number the For the for which enrolled X.XXX. concentration the X endpoint trial in of this the the X.X% of reproxalap enrolled trial, was value Phase Phase Xb approximately clinical patients one-third, in P
as the As the RESET trial year we in we in second mentioned year over Joshua therapeutic on expand X results our unmet novel half announce back Joshua? I’d from continue mission Phase SOLACE for to Research anterior with we providing Part week trial of you expect with patients need. last Development medical of review uveitis end updating the And year to results. Syndrome. options throughout financial noninfectious catalyst call of to turn this to and to build look to the Day that and this forward at like We X our XXXX Sjögren-Larsson
